Clinical Trials on Type 2 Diabetes Mellitus (T2DM) in Poland

Total 1094 results

Novo Nordisk A/S

Withdrawn

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

Thailand, Malaysia, Poland, India, Hungary, Mexico, Brazil, United States, Croatia, Romania, Bulgaria, Greece, Serbia
Oregon Health and Science University
The Leona M. and Harry B. Helmsley Charitable Trust

Completed

The Multi-Sensor Distance Accuracy Study

Type 1 Diabetes Mellitus

United States
Eli Lilly and Company

Completed

Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico
Reata, a wholly owned subsidiary of Biogen

Completed

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Diabetic Nephropathy | Type 2 Diabetes | Chronic Kidney Disease

United States
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Diabetes Mellitus, Type 2

United States, Canada
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (ALBUM)

Type 2 Diabetes | Chronic Kidney Disease

Spain, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, United Kingdom
Novo Nordisk A/S

Completed

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes (LIRA-PRIME)

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Serbia, Turkey, Russian Federation, India, Latvia, Puerto Rico, Lebanon, Colombia
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (PIONEER 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Japan, Puerto Rico, Canada, France, Mexico, Poland, Russian Federation, Greece
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Australia, Canada, Germany, Spain, Taiwan, Hungary, Poland, Korea, Republic of, Austria, New Zealand, United Kingdom, Czechia, Puerto Rico
Novo Nordisk A/S

Completed

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study (SWITCH PRO)

Diabetes Mellitus, Type 2

United States, Slovakia, Canada, South Africa, Puerto Rico, Poland
Lexicon Pharmaceuticals
Sanofi

Terminated

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED)

Heart Failure | Chronic Kidney Diseases | Type 2 Diabetes Mellitus

Estonia, Belgium, Sweden, Italy, China, United States, Canada, Bulgaria, Chile, Denmark, Hungary, Latvia, Mexico, Russian Federation, Serbia, Spain, Portugal, Romania, Turkey, Poland, Lithuania, Argentina, Australia, Brazil, Czechia, France, Georg... and more
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, United Kingdom, Ireland, France, South Africa, Ukraine
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (onset® 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Israel, Russian Federation, Slovakia, Canada, Serbia, United Kingdom, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs (CONCLUDE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Canada, Denmark, Hungary, Serbia, Germany, Greece, Romania, Estonia, Norway
Oregon Health and Science University

Completed

Exercise Physiology Study

Hypoglycemia | Type 1 Diabetes Mellitus

United States
Eli Lilly and Company

Recruiting

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Diabetes Mellitus, Type 2

United States, Canada, Mexico, Argentina, Puerto Rico
Eli Lilly and Company
OPKO Health, Inc.

Completed

A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico
Novo Nordisk A/S

Completed

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus (DUAL™ VIII)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Italy, Mexico, Poland, Russian Federation, Slovakia, United Kingdom, Argentina, Norway, Turkey, Israel, Czechia, South Africa, Hungary, Brazil
Medical University of Warsaw

Completed

Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal

Diabetes Mellitus, Type 1

Poland
Novartis Pharmaceuticals

Completed

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Korea, Republic of, Latvia, Peru, Lithuania, Israel, Norway, Finland, Argentina, Austria, Belgium, Germany, Greece, Guatemala, Hungary, India, Italy, Mexico, Poland, Romania, Slovakia, Venezuela
Amsterdam UMC, location VUmc

Completed

The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Insulin Sensitivity/Resistance

Netherlands
Boehringer Ingelheim

Completed

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

Diabetes Mellitus, Type 2

United States, Canada, Mexico, Philippines, Romania, Russian Federation, Ukraine
Mannkind Corporation

Completed

A 2-Month Safety Follow-Up Trial

Type 1 Diabetes | Type 2 Diabetes

United States, Brazil, Canada, Russian Federation
Novo Nordisk A/S

Completed

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily (TITRATE™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Withdrawn

SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (SUSTAIN SWITCH)

Diabetes Mellitus, Type 2

United States, Sweden, Austria, Finland
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) (COMBINE 2)

Diabetes Mellitus, Type 2

United States, China, Taiwan, Canada, Switzerland, Japan, Brazil, Russian Federation, Hungary, Greece, France, Israel, Sweden, Slovakia
GlaxoSmithKline

Completed

A Study In Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Canada, Australia, Philippines, Mexico, Puerto Rico
AstraZeneca

Completed

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Non-Insulin-Dependent

United States
Sanofi

Completed

Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment (LANCELOT)

Diabetes Mellitus, Type 2

Brazil, Thailand, Slovakia, Poland, Netherlands, Kuwait, Mexico, Korea, Republic of, Czech Republic, Egypt, France, Italy, Romania, Russian Federation, Sweden, Switzerland, United Arab Emirates
Boehringer Ingelheim

Completed

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Australia, Canada, Czech Republic, Russian Federation, Ukraine
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Puerto Rico
Eli Lilly and Company

Completed

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes (IMAGINE 6)

Diabetes Mellitus, Type 2

United States, Canada, Germany, Korea, Republic of, Hungary, Spain, Puerto Rico, Poland, Mexico, Argentina, Czechia
Novo Nordisk A/S

Completed

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, United Kingdom, Canada, Austria, Serbia, Germany, South Africa, Malaysia, Czechia
Novo Nordisk A/S

Completed

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)

Diabetes Mellitus, Type 2

Croatia, India, Poland, Spain, Serbia, Germany, Slovakia, Slovenia, Turkey, Hungary, Greece, Czechia, Bulgaria, South Africa, Romania, Bosnia and Herzegovina, Estonia, Portugal, Latvia, Lithuania, North Macedonia
Novo Nordisk A/S

Completed

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Croatia, Italy, Russian Federation, Spain, Canada, Serbia, Slovakia, Germany, Greece, Korea, Republic of, Czechia, Puerto Rico, Bulgaria, Romania, Argentina, Ukraine
Novo Nordisk A/S

Completed

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-6)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Denmark, Sweden, Austria, Germany, Macedonia, The Former Yugoslav Republic of, Slovenia, France, Switzerland, Norway, Spain, Ireland, Finland, Romania
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

Diabetes Mellitus, Type 2

United States
Anji Pharma

Suspended

Investigational Study of Delayed Release Metformin (DREAM-T2D)

Diabetes Mellitus, Type 2

Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
Novo Nordisk A/S

Completed

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes (STEP HFpEF DM)

Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

United States, Spain, Hungary, United Kingdom, India, Netherlands, Germany, Japan, Canada, Czechia, Argentina, Austria, Israel, Italy, Poland, Sweden
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, United Kingdom, Canada, Sweden, Ireland, Argentina, Brazil, Lebanon, Malaysia, Mexico, Italy
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Puerto Rico, Slovakia, Canada, South Africa, United Kingdom, Czech Republic
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes (Ellipse™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Russian Federation, Spain, United Kingdom, Austria, Belgium, Mexico, Sweden, Israel, Taiwan, Hungary, Malaysia, Serbia, Turkey, Denmark, Greece, Thailand, North Macedonia, Norway, Portugal, Germany, Romania and more
Sanofi

Completed

Obese Patients With Type 2 Diabetes (RIO-Diabetes)

Obesity | Diabetes Mellitus, Non-Insulin-Dependent | Obesity in Diabetes

United States, France, Canada, Poland, Germany, Netherlands, Belgium, Czech Republic, Argentina, Finland, United Kingdom
Eli Lilly and Company

Completed

A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico, Russian Federation, Canada, Denmark, India, Poland, Korea, Republic of, Brazil, Argentina, Mexico, South Africa
Novo Nordisk A/S

Completed

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (PIONEER 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Japan, Russian Federation, United Kingdom, France, Mexico, South Africa, Turkey, Argentina, Germany, Romania, Brazil, Ukraine
Novo Nordisk A/S

Completed

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (PIONEER 6)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Italy, Mexico, United Kingdom, Canada, Denmark, Spain, Netherlands, Malaysia, Taiwan, Germany, Poland, Turkey, Argentina, South Africa, Romania, Thailand, Algeria, Brazil
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes (DUAL™ II)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Denmark, Hungary, Slovenia, Switzerland, Bulgaria
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (SUSTAIN 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, Austria, Japan, Norway, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (onset® 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Argentina, Slovenia, Romania
GlaxoSmithKline

Completed

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Diabetes Mellitus, Type 2

United States, Canada, Germany, Estonia, Russian Federation, South Africa, India, Ukraine, Mexico, Greece, New Zealand, Poland, Czechia, Lithuania, Romania, Puerto Rico

Clinical Trials on Type 2 Diabetes Mellitus (T2DM) in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations